The enhanced value of combining conventional and "omics" analyses in early assessment of drug-induced hepatobiliary injury.
The InnoMed PredTox consortium was formed to evaluate whether conventional preclinical safety assessment can be significantly enhanced by incorporation of molecular profiling ("omics") technologies. In short-term toxicological studies in rats, transcriptomics, proteomics and metabolomics data were collected and analyzed in relation to routine clinical chemistry and histopathology. Four of the sixteen hepato- and/or nephrotoxicants given to rats for 1, 3, or 14days at two dose levels induced similar histopathological effects. These were characterized by bile duct necrosis and hyperplasia and/or increased bilirubin and cholestasis, in addition to hepatocyte necrosis and regeneration, hepatocyte hypertrophy, and hepatic inflammation. Combined analysis of liver transcriptomics data from these studies revealed common gene expression changes which allowed the development of a potential sequence of events on a mechanistic level in accordance with classical endpoint observations. This included genes implicated in early stress responses, regenerative processes, inflammation with inflammatory cell immigration, fibrotic processes, and cholestasis encompassing deregulation of certain membrane transporters. Furthermore, a preliminary classification analysis using transcriptomics data suggested that prediction of cholestasis may be possible based on gene expression changes seen at earlier time-points. Targeted bile acid analysis, based on LC-MS metabonomics data demonstrating increased levels of conjugated or unconjugated bile acids in response to individual compounds, did not provide earlier detection of toxicity as compared to conventional parameters, but may allow distinction of different types of hepatobiliary toxicity. Overall, liver transcriptomics data delivered mechanistic and molecular details in addition to the classical endpoint observations which were further enhanced by targeted bile acid analysis using LC/MS metabonomics.
Ellinger-Ziegelbauer
Heidrun
H
Bayer Schering Pharma AG, Wuppertal, Germany. heidrun.ellinger-ziegelbauer@bayerhealthcare.com
Adler
Melanie
M
Amberg
Alexander
A
Brandenburg
Arnd
A
Callanan
John J
JJ
Connor
Susan
S
Fountoulakis
Michael
M
Gmuender
Hans
H
Gruhler
Albrecht
A
Hewitt
Philip
P
Hodson
Mark
M
Matheis
Katja A
KA
McCarthy
Diane
D
Raschke
Marian
M
Riefke
Björn
B
Schmitt
Christina S
CS
Sieber
Max
M
Sposny
Alexandra
A
Suter
Laura
L
Sweatman
Brian
B
Mally
Angela
A
D000818:Animals; D056486:Chemical and Drug Induced Liver Injury / Q000175:diagnosis / Q000235:genetics*; D002780:Cholestasis, Intrahepatic / Q000139:chemically induced / Q000175:diagnosis / Q000235:genetics*; D064420:Drug-Related Side Effects and Adverse Reactions / Q000139:chemically induced / Q000175:diagnosis / Q000235:genetics*; D020869:Gene Expression Profiling / Q000379:methods*; D008297:Male; D055432:Metabolomics / Q000379:methods*; D040901:Proteomics / Q000379:methods*; D051381:Rats; D017208:Rats, Wistar